A34 CLINICAL AND CELLULAR STUDIES IN ALLERGIC DISEASE: Microsphere-Encapsulated Allergen Epitope Delivery Enhances Activation Of Bone Marrow-Derived Dendritic Cells For Allergen-Specific Immunotherapy

Rationale: Subcutaneous or oral allergen-specific immunotherapy using allergen encapsulated within biodegradable poly(D, L-lactic-co-glycolic) acid (PLGA) microspheres and CpG (Th1 adjuvant) has been shown in mice to significantly increase allergen-specific IgG2a antibodies and Th1 immunity compared...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Main Authors: Killingbeck, S S, Ge, M Q, Flayer, C H, Larson, E D, Haczku, A
Format: Article
Language:English
Subjects:
Allergies
Bone marrow
Dendritic cells
Immunotherapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rationale: Subcutaneous or oral allergen-specific immunotherapy using allergen encapsulated within biodegradable poly(D, L-lactic-co-glycolic) acid (PLGA) microspheres and CpG (Th1 adjuvant) has been shown in mice to significantly increase allergen-specific IgG2a antibodies and Th1 immunity compared to traditional treatment with allergen injection alone. Methods: Bone marrow cells from WT C57BL/6 mice were cultured with Flt3L and GM-CSF for 11 days, then treated with 2.5 pg/mL MPLA and 1 mg/mL PLGA microspheres encapsulating OVA + CpG or MPLA + OVA alone and co-cultured for an additional week.
ISSN:1073-449X
1535-4970